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Abstract
Congenital muscular dystrophies (CMDs) are a wide group of muscular disorders that manifest with very early onset
of muscular weakness, sometime associated to severe brain involvement.
The histologic pattern of muscle anomalies is typical of dystrophic lesions but quite variable depending on the
different stages and on the severity of the disorder.
Recent classification of CMDs have been reported most of which based on the combination of clinical, biochemical,
molecular and genetic findings, but genotype/phenotype correlation are in constant progression due to more
diffuse utilization of the molecular analysis.
In this article, the Authors report on CMDs belonging to the group of dystroglycanopathies and in particular on the
most severe forms represented by the Fukuyama CMD, Muscle-Eye-Brain disease and Walker Walburg syndrome.
Clinical diagnosis of infantile hypotonia is particularly difficult considering the different etiologic factors causing the
lesions, the difficulty in localizing the involved CNS area (central vs. peripheral) and the limited role of the
diagnostic procedures at this early age.
The diagnostic evaluation is not easy mainly in differentiating the various types of CMDs, and represents a
challenge for the neonatologists and pediatricians. Suggestions are reported on the way to reach a correct
diagnosis with the appropriate use of the diagnostic means.
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Background
Muscular dystrophies (MDs) encompass a group of
disorders presenting with skeletal muscle weakness,
peculiar histological muscle alterations and consisting in
abnormal muscular architecture with loss of muscular
tissue (Fig. 1) and variable outcomes. In some cases,
involvement is not limited to muscles, but it may affect
other organs (e.g., heart). Until recently, MDs were
clinically distinguished into six categories represented by
Duchenne MD (DMD) and Becker MD; limb-girdle MD
(LGMD); distal myopathies; congenital MD (CMD);
facio-scapulo-humeral MD; and myotonic dystrophy.
The recent diffusion of genetic investigations has notably
enlarged the knowledge in the field of muscle disorders,
and, at present, more than 50 forms of MDs are
distinguished on the basis of specific genetic mutations,
each one with a different pattern of muscle distribution,
different involvement of body organs other than the
skeletal muscles, and variable course. As recently
demonstrated in most of the MDs, a specific genotype/
phenotype correlation has been reported, even if in a
minor number of cases examples of a same gene
expressing multiple phenotypes have been reported [1].
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Congenital Muscular Dystrophies (CMDs) are an un-
common group of MD disorders characterized by early
onset of muscular weakness within 1 year of age and
manifesting with more or less severe neonatal hypotonia
as well as histologically presenting with features of
dystrophic lesions [2]. Muscle biopsies in patients with
CMDs show considerable variability but always exhibit
the characteristic pattern of dystrophic lesions: histologic
variability may be linked to the different stage of the dis-
order or reflect the severity of the disease or both [2].
The prevalence of CMDs is poorly known, and it is
roughly maintained in the range of 1/100.000 individ-
uals. In northeast Italy, as reported by Mostacciuolo [3],
the prevalence has been calculated to be around
0.68x105. Norwood et al. [4] in a study carried out with
the aim to assess the prevalence of the genetic muscle
disease in Northern England, report CMDs to be 0.76 ×
105. Recently, Graziano et al [5] in an Italian study
population report a total CMDs prevalence of 0.563 ×
105, specifically, in a total of 336 patients enrolled in the
study, 135 (40.2 %) showed alpha-dystroglican glycosyla-
tion deficiency with a point prevalence 0.226 × 105; lam-
inin alpha 2 deficiency was reported in 24.1 % with point
prevalence of 0.136 × 105; collagen VI deficiency was
registered in 20.24 % with a point prevalence of 0.114 ×
105. Mutations in SEPN1 and LMNA were less fre-
quently reported: 6.25 and 5.96 %, with point prevalence
of 0.035 × 105 and 0034 × 105, respectively.
Past and more recent CMDs classification
Several classifications have been proposed to distinguish
the different forms of CMDs. Parano et al. [6, 7]
distinguished different CMDs: 1) Classical CMD (with-
out mental retardation) a) with merosin deficiency and
b) with normal merosin; 2) CMD with forebrain
malformations-mental retardation: a) Cobblestone lis-
sencephaly syndromes including Fukuyama congenital
muscular dystrophy, Muscle-eye-brain disease, Walker-
Warburg syndrome, and isolated Cobblestone lissence-
phaly; b) CMD with occipital agyria; 3) CMD with
mental retardation (not otherwise classified); 4) Atypical
CMDs: a) Autosomal Dominant CMD, b) CMD with
central nervous system malformations and normal
intelligence including patients with cerebellar hypoplasia/
atrophy and patients with syringomyelia; c) CMD with
prominent extra-CNS manifestations with Hirschprung
disease and patients with severe cardiac disease; d) other
atypical syndromes including Ullrich syndrome/rigid
spine/”atonic sclerotic” CMD.
A classification of CMDs based on the combination of
clinical, biochemical, molecular, and genetic findings was
proposed by Voit and Tomè in 2004 [8] who distinguished
CMDs in four groups: 1) deficit of laminin alpha 2
(formerly known as “merosin”), primarily affecting the
basement membrane (MDC1A); 2) defects caused by an
abnormal glycosylation of alpha-Dystroglycan: Walker
Warburg syndrome (WWS), Muscle-Eye-Brain diseases
(MEB), Fukuyama CMD (FCMD), and MDC1B, MDC1C,
MDC1D; 3) disorders producing prominent contractures,
rigid spine, and Ullrich CMD; 4) primary or secondary
alpha 7 integrin deficiency.
More recently, Bonneman et al. [2] reported on the
currently recognized of CMD entities: a) laminin alpha 2
related CMD (primary laminin 2/merosin deficiency); b)
alpha-dystroglycan related dystrophies; c) congenital
disorders of glycosylation (CDG) with abnormal alpha-
dystroglycan glycosylation; d) collagen VI and Integrin-
related CMD forms; e) Intracellular and nuclear CMD
forms. In the group of alpha-dystroglycan related dystro-
phies, the authors include a) CMD with partial merosin defi-
ciency (MDC1B with locus in 1q42); b) LARGE related
CMD (MDC1D—gene LARGE); c) Fukuyama CMD, FCMD
gene, protein Fukutin; d) Muscle-Eye-Brain (MEB) genes
POMGnTI, FKRP, ISPD, TMEM5, Fukutin); e) Walker-
Warburg syndrome (WWS), genes POMTI, POMT2; FKRP,
ISPD, CTDC2, TMEM5, POMGnTI, B3GALNT2, GMPPB,
B3GNT1, SGK196, Fukutin); e) CMD/LGMD with Mental
Retardation (genes FKRP, POMTI, POMT2, ISPD, GMPPB);
f) CMD/LGMD without mental retardation including
MDC1C (genes FKRP, ISPD, GMPPB, Fukutin).
Fig. 1 Archive’s photo. Histological features of the patient with WWS showing the typical dystrophic lesions at the beginning of the disease with
initial lesions (left) and after 14 months with clear dystrophic features (right)
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Kang et al. [9], following the establishment of the
Guideline Development Subcommittee of the American
Academy of Neurology and the Practice Issues, distin-
guished the types of CMDs in the following major
categories: collagenopathies autosomal recessive (AR)
and autosomal dominant (AD) (also known as Collagen
VI related myopathies), including Ullrich CMD and
Bethlem myopathy; merosinopathies AR (also reported
as merosin-deficient CMD); dystroglycanopathies AR
(alpha-dystroglycan-related MDs) including FCMD,
MEB, WWS, and primary alfa-dystroglycanopathy,
MDDGA10, MDDGA11, MDDGA14. In the group of
unclassified CMDs, the authors include rigid spine
syndrome (SEPN1 and FHL1 genes), multiminicore
disease (SEPN1), and LGMD (LMNA gene).
Classifications, clinical features, and genotype/pheno-
type correlation in CMDs are constantly in progress due
to the worldwide use of molecular analysis and an
usually prolonged survival of the affected patients due to
a more suitable clinical assistance.
In this article, we want to point out our attention to
CMDs belonging to the group of dystroglycanopathies
(also reported as alpha-dystroglycan related MDs) [2]
and in particular on clinical features of the most severe
disorders of this group: FCMD, MEB disease, and WWS.
An infant with severe congenital hypotonia represents a
great clinical challenge for pediatricians. Establishing the
events that have caused the lesions, the difficulties in lo-
calizing the involved CNS (central vs peripheral), which
in some circumstance may concur, difficulty in perform-
ing and interpreting diagnostic procedures, particularly
in the early age, and distinguishing the different and
numerous types of peripheral neonatal hypotonia includ-
ing the different group of CMDs are all difficult tasks for
pediatricians who treat these children. An approach to
the clinical diagnosis to the different form of CMDs and
related conditions is reported.
defective glycosylation of alpha-dystroglycans
Defective glycosylation of alpha-dystroglycans is one of
the events that may cause CMDs. These disorders encom-
pass several conditions that range from early and severe
clinical involvements, as demonstrated by the WWS,
MEB, and FCMD, to later and less pronounced muscle
impairment and with/without comorbidity with other
body-organs [10–12]. Clinical presentation of this group
of disorders is heterogeneous, and this has led researchers
to consider them as a wide spectrum of the same entity.
Several genes have been implicated in the pathogenesis
of the alpha-dystroglycanopathies. Among these,
POMT1, POMT2, POMGnT, FCMD, Fukutin, and
LARGE genes are reported to code for specific or
putative glycosyl-transferases involved in the pathway of
alpha-dystroglycanopathies.
A multicenter Italian study carried out by Mercuri et al.
[13] in 81 CMDs with defective glycosylation of dystroglycan
gave the following results: WWS was diagnosed in six with
mutations identified in 4 (POMT1 in two, POMGnT1 in
one, LARGE in one); MEB/FCMD-like in 24 with mutations
identified in 13 (POMGnT1 in six, FKRP in three, POMT1
and POMT2 in two, respectively); CMD with cerebellar
involvement in 15 with mutations identified in 8 (POMT1 in
four, POMT2 in three, POMGnT1 in one); CMD with
mental retardation and normal MRI in 21 with mutations
identified in 10 (POMT1 in five, POMT2 in three and FKRP
in two); CMD with no mental retardation and normal MRI
was reported in 4 patients with mutations identified in 3
(POMT, FKRP and Fukutin, in one patient each).
CMDs are frequently associated to intellective delay
(ID) and structural brain involvement and Messina et
al [14] report a figure of 92 out of 160 CMDs
patients with cognitive impairment: patients affected
by alpha-dystroglycan deficiency were the majority (73/92,
79 %), mostly harboring mutations in POMGnT1 gene
(42/73, 57.5 %).
Fukuyama Congenital Muscular Dystrophy (FCMD)
FCMD was first reported by Fukuyama [15] in 1960.
The gene responsible for FCMD was found to be located
on chromosome 9q31-33 (FCMD or FKTN) [16]. Its
product, named fukutin, was identified by Kobayashi
et al. 2 years later [17]. Fukutin is a putative glycosyl-
transferase of 461 aminoacids. The clinical features of
FCMD reported in 15 patients by Fukuyama et al. [15,
18] were severe and consisted of hypotonia with an ex-
tremely early onset and a generalized distribution of the
affected regions, including facial muscles and proximal
muscles slightly more severely affected than the distal.
Joint contractures at an early stage such as those found
in congenital multiple arthrogryposis, and hypokinesia
were also reported. Moreover, some patients presented
with mental and speech retardation, febrile or afebrile
seizures, and pseudohypertrophy of the skeletal muscles
(found in about 50 % of the patients). Severe functional
disabilities and very slow progressive course were also
found. At the muscle biopsy, the patients presented with
severe degeneration and atrophy of the muscular fibers
and a high degree of proliferation of the connective
tissue: in particular, the proliferation was located in the
endomysium, differently from what usually happens in
DMD, in which an initial proliferation of the perimysium
is found [18]. Pre-requisite diagnostic criteria established
by Fukuyama et al. [15, 18] included the following: both
sexes equally affected, onset before the age of 8 months;
delayed motor development, generalized symmetric
weakness and hypotonia, decreased or absent deep tendon
reflexes; facial muscle involvement; elevated serum CK
activity; and muscle involvement with histologic features
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compatible with muscular dystrophy. The head circumfer-
ence was reported by these authors as small, and none of
the patients showed a head circumference above the
average. Cerebral involvement was also impressive with
mental retardation and speech delay manifesting in more
than half of the patients. The CT scan, performed in 22
patients by Fukuyama et al. [18], showed a decreased
radiodensity of white matter (marked in 18 % and mild in
23 %). Other anomalies within the CT scans consisted of
dilatation of lateral (59 %), third (41 %), and fourth ventri-
cles (28 %), cortical sulci (50 %), longitudinal cerebral
fissure (45 %), Sylvian fissure (91 %), and posterior cere-
bellar incisure (25 %). Kamoshita [19], using brain MRIs
in FCMD patients, reported anomalies consisting of
micropolygyria of the cerebrum and cerebellum with loss
of cytoarchitecture, aberrant, and deviated pathway of the
pyramidal tract. No patients with hydrocephalus were
reported. From the ocular investigation in 20 FCMD
patients, Honda et al. [20] reported frequent myopia and
weakness of the ocular and orbicular muscles and in some
cases optic nerve atrophy.
During the following years, the clinical features of the
FCMD, as initially reported by Fukuyama et al., substan-
tially have not changed. It appears evident that the
affected patients show a variable degree of clinical mani-
festations, including variability into the members of the
same family. The muscle involvement appears most
frequent before and during the neonatal age with weak-
ness and hypotonia and the history of poor fetal move-
ments. The newborns appear floppy, and the cry is feeble.
Usually, the look is vivid. Pulmonary infections may be
frequent in the first months of life. Hypertrophy of the
calves and quadriceps, cognitive delay, seizures, and diffi-
culty in walking may later be present. Ophthalmologic
examination may show retinal folding, fusion, focal dys-
plasia, and detachment [21]. The brain MRI may present
with transient white matter abnormalities, occipital
cobblestone cortex, hypoplasia of the pons and cerebellar
vermis [22], and cerebral and cerebellar micropolygiria, as
previously reported by Fukuyama et al. [18]. The main
clinical features of FCMD have been recently summarized
by Bonnemann et al. [2] and consist of high prevalence in
the Japanese population, inability to walk, epilepsy and
mental retardation, clinical overlap with MEB syndrome,
but less severe eye involvement. Lissencephaly type II/
pachygyria, hypoplastic brainstem, and cerebellar abnor-
malities are the most frequent CNS imaging findings [2]
Muscle eye brain (MEB) disease
Muscle-eye-brain is known as “MEB disease” and is
characterized by CMD, structural eye abnormalities, and
cerebral malformations, first reported by Santavuori
et al. in 1978 [23]. The authors reported on a series of 9
children (8 males, 1 female) and two adult siblings. The
patients came from two different areas of Finland, and
for some years the disorder was maintained to affect
only the Finnish population. In their first presentation,
the authors referred that patients with this disorder
had poor psychomotor development, hypotonia, and
ocular symptoms, including nystagmus with suspicion of
glaucoma. The age of referral was reported as an average
of 2.2 months. Tendon reflexes were normal at birth but
weak or absent by 1 year of age. The motor development
was drastically retarded. Only one of the children and the
two adult patients could sit or move around; in one of
the reported children, the acquired condition was lost
after a prolonged convulsive episode. All patients suffered
from convulsions, and two presented with myoclonic
jerks. The head circumference developed normally with
only one exception. In some of the patients, facial dys-
morphism was also reported: the forehead was high and
prominent with a wide fontanel, the mid-face was flat,
and the nose and filtrum short. The patients suffered
from severe visual failure with congenital glaucoma and
hypoplastic choroid; optic atrophy was found in 7 pa-
tients and optic coloboma in 3. The laboratory investiga-
tions displayed an increased level of serum creatine
phosphokinase (CK) present since the neonatal period
and persisting elevated in all children with values ranging
from 150 to 1550 IU/ml. The EMG showed slight myo-
pathic changes with progressive course during the ages.
Muscle histology was similar in all patients and consisted
of typical signs of muscular dystrophy at various stages.
A few years after the Santavouri’s report [23], Dambska
[24] described the “cerebro-ocular muscular syndrome” on
three siblings who manifested with dysmorphic face, hypo-
tonia, areflexia, and failure to thrive. In these patients, eye
anomalies consisted of corneal opacity, cataracts, and dys-
genesis of the anterior chamber. Agyric hemispheres, poly-
microgyria in several cortical segments, and severe cortical
disorganization were the cerebral malformations reported
at MRI. The muscle biopsy disclosed a severe muscular
dystrophy. The authors [24] defined these patients as
affected by a variant of Fukuyama congenital cerebro-
muscular dystrophy, but the clinical features of the patients
recall those of MEB disease. Patients with similar
clinical features of MEB were also reported by Kor-
inthenberg et al. [25] in three German patients, dem-
onstrating the wide diffusion of this condition that
affected not only patients of Finnish origin.
The clinical and molecular aspects of MEB disease are
typical and specific, but the grade of severity of each
organ affected is quite variable. The disorder is inherited
in autosomal recessive pattern and is associated with
mutations in the gene at 1p34-p32 that codifies
POMGnT1, a glycosyl transferase. All the mutations in
POMGnT1 cause a complete loss of function of the
glycosyltransferase, but, as reported by Hehr et al. [26],
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the type of mutation appears to not be related to the
variability in clinical severity. As reported in the litera-
ture, the most frequent clinical anomalies reported in
MEB are the congenital muscular dystrophy, constantly
observed and sometimes as a single (pure) manifestation:
the eye anomalies are usually congenital and may
include severe myopia, glaucoma, optic nerve, and
retinal hypoplasia. The cortical malformations may be
present with defective migration ranging from pachy-
polymicrogyria and agyria, white matter abnormalities,
and anomalies of the brainstem and cerebellum [26].
Taniguchi et al. [27] reported on patients first diagnosed
as FCMD, MEB, or WWS, respectively. They demon-
strated that MEB is caused by loss of function mutations
in the gene encoding protein O- linked mannose Beta 1 2-
N-acetylglucosaminyltransferase I (POMGnT1). The dis-
order is present in different races with a worldwide distri-
bution, and it has a broader clinical spectrum than
previously expected. In a recent survey in Turkish pa-
tients, Yis et al. [28] from a cohort of 34 patients affected
by CMD, reported twelve patients who presented signs di-
agnosed as MEB disease. The most common mutation re-
ported in 66 % of patients was c.1814G > A (p. R605H).
Two novel mutations were identified by these authors,
who referred that all the patients showed muscular hypo-
tonia at birth followed by variable degree of spasticity and
exaggerated deep tendon reflexes, secondary to brain in-
volvement. In the later stage of life, the mean serum CK
values were 2485.80 + - 1304.54 IU/L (700 to 4267 IU/L).
The most common ophthalmologic and cerebral anomal-
ies consisted of cataracts, retinal detachment, periven-
tricular white matter abnormalities, ventriculomegaly,
pontocerebellar hypoplasia, and multiple cerebellar cysts.
Falsaperla et al. reported a 13 year-old girl with a long-
term survival, demonstrating the wide variability of MEB
disease [29]. The molecular analysis displayed mutations
in the PDHGT1 gene. The child showed failure to thrive
with height and weight under the 3rd percentile and a
head circumference around the 3rd percentile. Her neuro-
logical examination showed speech delay, strabismus,
proximal and distal weakness with hypotonia of the upper
limbs, and signs of hypertonia in the lower limbs with
slight contracture of the fingers and wrist. The eyes
presented with severe myopia and retinal dysplasia. The
MRI showed cortical gyration of the frontal lobes, micro-
polygyria of the temporal lobe, and bilateral microcystic
degeneration of the cerebellar cortex. The course pre-
sented by this girl was milder than usually reported and is
a confirmation of the variable clinical aspect of the
disorder. As reported by Bonnemann [2], MEB disease
may involve different genes such as POMGnTI, FKRP,
Fukutin, ISPD, TMEM5 with clinical features in summary
consisting of mainly severe congenital weakness, inability
to walk, spasticity and motor deterioration, mental
retardation, and severe eye involvement. The brain MRI
reflects what has been reported in FCMD with lissence-
phaly type II/pachygyria, brain stem and cerebellar
anomalies and cysts.
Walker Warburg Syndrome (WWS)
The syndrome is named after Walker [30], who described a
patient with lissencephaly, and Warburg [31] who reported,
in 1978, a 6-year old boy who was severely retarded, hypo-
tonic, and unable to sit up even with support. As described
by Warburg [31], the boy was born from consanguineous
parents (first cousins). During the infancy, the child
suffered from unexplained diarrhea and failure to thrive.
His right eye was microphthalmic with retinal detachment
and hydrocephalus was also present and treated with a
shunt. In the first year of life, he developed scoliosis and
secondary contractures of arms and legs. At the time of the
admission, Warburg reported that the child was blind and
severely mentally retarded with a communicating hydro-
cephalus, right microphthalmia with congenital retinal
detachment, and a left abortive falciform fold.
A family was reported from Catania, Italy, in whom
three members suffered from congenital hydrocephalus
and ocular abnormalities [32]. In two of them, the mus-
cular tone was normal, while the third presented with
cerebral, eye, and muscle involvements. The patient was
born by caesarean delivery with hydramnios. The mother
mentioned that fetal movements were present but feeble.
The head circumference increased rapidly since the first
days of life and reached the diameter of 42 cm at 1
month. Severe muscular hypotonia was present with the
first three fingers flexed and absence of deep tendon
reflexes and muscle enzymes were increased. At autopsy,
the child showed a classic lissencephaly with midline
fusion of frontal lobes with absence of lobi olfactorii.
Coronal sections showed widespread cortical malforma-
tions consisting of agyria, pachygyria, and/or micropoly-
gyria with many subcortical ganglion heterotopias. The
histological evaluation of muscle affected showed a
severe degeneration of muscle fibers with severe inter-
fascicular fibrosis and lipomatosis (Fig. 1). The authors
concluded that the reported patients could represent a
clinical variable of the Warburg syndrome and suggest
some links with Fukuyama congenital muscular dystrophy
and/or with the so-called brain-eye-muscle disease of
Santavuori. The same authors [32] were among the first to
anticipate and to suggest that the three syndromes
(Walker-Warburg, Fukuyama, and “Santavuori”) could be
considered as three variants of the same disease.
WWS is reported to be genetically heterogeneous. The
genes involved are POMT1, POMT2, and less frequently
POMGnT1, FKRP, Fukutin, and LARGE [33–37]. The
clinical picture of this disorder is particularly severe as
most of the children do not survive beyond the first
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years of life. A clinical description of the disorders has
been reported by Dobyns et al. [34] with detailed clinical
description of the disorder; aside the severe congenital
muscular dystrophy, the brain malformation is
constantly present and represented by lissencephaly type
I with cobblestone cortex, obstructive hydrocephalus,
neuronal heterotopias, corpus callosum agenesis, fusion
of the hemispheres, and ponto-cerebellar hypoplasia
with fourth ventricle dilatation (Figs. 2 and 3). Occipital
encephalocele and Dandy Walker cyst may be present.
The eye anomalies involve both anterior and posterior
chambers with retinal detachment and blindness. Micro-
phthalmia, thalamus, optic nerves hypoplasia, colobomas
and iris malformation, cataract, and megalocornea may
be also found. The clinical features may be also associ-
ated, even if not frequently, with facial dysmorphism
and cleft lip or palate [38].
Other less known types of CMDs belonging to
alpha-dystroglycan related dystrophies
Congenital muscular dystrophy type 1C (MDC1C)
This subtype of CMD was first reported by Brockington
et al. [39], who identified a new member of the fukutin
family of proteins, FKRP, with the gene mapping to
chromosome 19q13.3. The disorder manifests in the first
few weeks of life with CMD and marked increase of
serum CK. Several patients present with normal
intelligence and normal brain structures on brain
imaging. In the young adult age, the patients show heart
involvement, severe weakness, and wasting of the
shoulder girdle muscles; hypertrophy and weakness of
the leg muscles with calf and thigh hypertrophy and
severe respiratory failure are also recorded. The MDC1C
follows the nomenclature previously established for the
MDC1A related to CMD with a primary laminin apha 2
deficiency and for MDC1B related to a secondary laminin
alpha2 deficiency and calf hypertrophy linked to 1q42.
The group MDC1C also includes clinical features of
CMD/LGMD involving different genes (FKRP, Fukutin,
ISPD, GMPPB), which manifests with early onset
weakness and early onset LGMD without brain involve-
ment and cardiomyopathy.
CMD with partial merosin deficiency (MCD1B)
This form manifests with variable deficiency of the
glycosylated aDG epitope and secondary laminin alpha 2
deficiency. The muscle involvement manifests with prox-
imal limb girdle weakness, muscle hypertrophy, particu-
larly in the calf, and early respiratory failure [40].
LARGE related CMD (MDC1D)
This disorder has been initially reported by Longman et
al. [41] in a 17-year-old girl who displayed weakness
some months after birth and manifested severe mental
retardation. Failure of brain migration and white matter
anomalies with abnormal electroretinogram were also
reported. This anomaly may disclose some clinical
features of MEB and/or WWS.
The muscle biopsy in the case of Longman et al. [41]
showed a severe dystrophic pattern and a decreased
alpha-dystrogycan at immunolabeling.
Fig. 2 Archive’s photo. The same patient. Macroscopic examination,
showing severe architectural disarrangement with clear signs
of lissencephaly
Fig. 3 A new case of WWS showing severe lissencephaly lesions
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A few years ago, two Sicilian siblings, a boy and a girl,
born from consanguineous parents with congenital mus-
cular dystrophy and peculiar phenotype were reported
by Voit et al. [42]. In these patients, the genetic causes
were unknown, but several investigations with linkage
analysis allowed the authors to exclude the candidate
loci on chromosomes 1q32, 6q2, and 9q31. The gene
locus for MCD1B on chromosome 1q42 was also
excluded as was laminin alpha 2, laminin beta 2, and
alpha dystroglycan, which showed normal results at
immunocytochemistry of the muscle membrane pro-
teins. The siblings showed severe generalized muscle
weakness, including facial muscles, marked level of CK
(ranging from 200 to 700 U/L), and histological
alterations compatible with muscular dystrophy. In
addition, both children showed a peculiar phenotype
with adducted thumbs and toe contractions. Ptosis,
external opthalmoplegia, mild mental retardation, and
mild cerebellar hypoplasia on MRI were reported [42].
Neonatal hypotonia: a challenge to reach the diagnosis
As previously mentioned, the causes of the neonatal
hypotonia are several and to recognize the events that
have provoked the disorders represents a great challenge
for the pediatricians. Several conditions may manifest
with infantile hypotonia, including anomalies of the
central or peripheral nervous system with involvement
of the spinal cord, anterior horn cell, peripheral nerves,
neuromuscular junction, and muscles. The term “floppy
Infant” is referred to as the most severe clinical form of
hypotonia, and it is related to a child of an age ranging
from first days to 1 year of life, presenting with severely
reduced or absent muscle mobility.
History and clinical examination
The diagnostic evaluation includes detailed family, preg-
nancy and, perinatal history. General physical examination
to exclude malformative anomalies and body structural
defects. The muscle tone is evaluated according to the
standard maneuvers for hypotonic infant such as “pull to
sit”, the “horizontal” and “vertical suspension” (Figs. 4, 5
and 6). Suggestive of a prenatal origin of the hypotonia in
infancy are the following: family history (consanguineity,
familial muscle disorder); pregnancy history (reduced fetal
movements, polyhydramnios, vertex presentation); general
physical examination at birth (joint contractures, pes
cavus, skin dimples, sucking and swallowing difficulty,
reduced or absent patellar reflexes). Physical examination
is also directed to exclude malformative anomalies involv-
ing face, extremities, heart and genital organs and classical
syndromic disorders [43].
The distinction between central and peripheral ner-
vous system attainment may be only indicative since
both these structures may be clinically affected, and both
structural anomalies may co-exist in the same affected
infants in a variable expression. In general, severe weak-
ness with reduced or absent antigravitary movements,
poor spontaneous movements, absent tendon reflexes,
marked head lag and alert look are consistent with
hypotonia of peripheral origin. Evaluation of the cry, suck,
facial expression, antigravity movements (as clinical clue
of muscular strength), resistance to strength testing, and
respiratory capacity are also to be established [44]. Infants
with central involvement tend to show an unexpressive
look, usually normal strength with hypotonia and
increased or normal patellar reflexes, facial dysmorphism,
malformative anomalies neonatal seizures, and history of
neonatal distress. However, the clinical examination in the
case of a floppy infant needs to be supported by laboratory
investigations including assessment for intrauterine or
Fig. 4 Physical examination of the hypotonic child: “Pull to
sit” maneuver
Fig. 5 Physical examination of the hypotonic child: “horizontal
suspension” maneuver
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perinatal infections, TORCH, hemogram, blood gas ana-
lysis, erythrocytes sedimentation rate, and PCR. Investiga-
tions for muscle disorders include creatine kinase (CK),
aldolase, alanine aminotransferase (ALT), or aspartate
aminotransferase (AST). Other recommended investiga-
tions include ammonia, lactate, aminoacids, organic acids,
very long chain fatty acids, carnitine/acylcarnitine profile,
7 dehydrocholesterol, isoelectric focusing of the sialo-
transferine, N- and O- glycan analysis, and galactose 1-
phosphatase that may lead to the diagnosis of hypotonia
of metabolic origin. An increased CK, aldolase, ALT and
AST are usually indicative of a dystrophic process. The
diagnosis of Prader-Willi syndrome should be considered
and excluded through the methylation analysis of the
chromosome region of 15q11-q13. Specific lysosomal
enzyme testing for Pompe disease should be performed
when hypotonia is associated to cardiomyopathy. EMG
and NCV in infancy are technically difficult to be carried
out, and the interpretation of the data remain sometime
doubtful. These investigations are not as conclusive for
the diagnosis as they may be at older age. EMG could be
useful in distinguishing central vs. peripheral neuropathy
or muscle involvement. A neurogenic pattern shows
increased amplitude of action potentials; a myopathic
pattern is characterized by reduced action potentials and
increased interference; a myotonic pattern shows in-
creased insertional activity, while a myasthenic pattern an
abnormal repetivity. EMG is not advisable in case of
suspected spinal muscular atrophy (SMA): clinical exami-
nations, decreased deep tendon reflexes and the absence
of antigravitary movements are classically suggestive for
the diagnosis. NCV may be useful in displaying hereditary
motor sensory neuropathies. Muscle biopsy is advisable
since the basic histology may show signs of myopathic,
neuropathic, or dystrophic changes. Use of Immunohisto-
chemical techniques and electron microscopy may be
worthy to identify the types of congenital myopathies and
to distinguish different types of CMDs.
Ophthalmologic evaluation, electrocardiogram, elec-
troencephalogram, and brain MRI should also be carried
out according to the clinical examination.
Among the group of floppy infants of peripheral origin,
differential diagnosis is also difficult, including non-
neuromuscular genetic conditions such as Prader-Willi
syndrome [45]. Hypotonia and weakness are characteristic
signs present aside CMDs, in very early SMA, in congeni-
tal myotonic dystrophy, in congenital myasthenic
syndromes, and in congenital myopathies. These disorders
need to be distinguished from classical CMDs (FCMD,
MEB, WWS), and the last one must be differentiated by
the different types and subtypes of CMDs [45].
Very early Spinal Muscular Atrophy (Fig. 7) is inher-
ited with autosomal recessive modality. The neonatal
patients show hypotonia and weakness mainly proximal
and symmetrical with fasciculations of the tongue and
intention tremor. The look is vivid, and the deep tendon
reflexes are absent. Diagnosis is linked to SMN1 copy
number variation.
Congenital Myotonic Dystrophy (Steinert disease) (Fig. 8)
is the most frequent neuromuscular disorder in the
neonatal period. It is caused by a CTG-repeat expansion in
Fig. 6 Physical examination of the hypotonic child: “vertical
suspension” maneuver
Fig. 7 Infant with early SMA. Note the severe hypotonia, the vivid
look, severe involvement of diaphragm, and intercostal muscles
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DMPK. The pregnancy history displays reduced fetal
movements and poli-hydramnios. Clinical signs are present
at birth. Affected infants show deficit of diaphragm and
intercostal muscle functions and facial diplegia. Arthrogry-
posis and club feet may be noticed since birth. The EMG is
usually not diagnostic at birth, but it may give a positive
result subsequently. Multiple RNA splicing defects have
been recognized, leading to classify this disorder as a
“spliceopathy” [46, 47].
For the congenital myasthenic syndrome, two forms are
classically recognized: 1) Myasthenia Gravis is the transient,
acquired neonatal myasthenia present at birth or within the
first 3 days of life. The hypotonia is generalized and severe.
The patients show feeding difficulties with failure in suck-
ing and swallowing, facial weakness, and feeble cry. Ptosis
and ophthalmoplegia are frequently present, and these signs
may be useful for obtaining a correct diagnosis.
2) The Congenital myasthenia manifests with failure of
the bulbar, ocular, limbs, and respiratory muscles. ECG
may show heart block. EMG may be useful for diagnosis.
The response to treatment with acetylcholinesterase
inhibitors is diagnostic.
The patients with congenital myopathies (CMs) (Fig. 9)
present at birth with severe generalized muscle weakness,
facial weakness, and ophthalmoparesis. Peculiar structural
or developmental abnormalities in absence of dystrophic
lesions in the muscles are the histopatological features.
The most known forms include the following: centronuc-
lear myopathy-including myotubular myopathy) (MTM1,
DNM2, MYF6, CCDC78, BIN1 genes); core myopathy
including minicore (RYR1, SEPN1, TTN, MYH7 genes);
nemaline myopathy (TPM3,NEB,ACTA1, TPM2, TNNT1,
KBTBD13, CFL2 genes); congenital fiber-type dispropor-
tion ACTA1, SEPN1, TPM3, TPM2, MYL2 genes). In
these disorders, the histochemistry or electron micro-
scopic investigations are diagnostic [46].
The muscle biopsy, together with specific molecular/
genetic examinations, remains the gold standard for the
diagnosis of specific CMDs and similar conditions.
Muscle analysis is worthy for obtaining a correct diagno-
sis. The analysis should include the general histologic
structure, histochemical and immunohistochemical
reactions, and possibly specific enzyme quantification. In
some cases, the investigation should be extended to
electron microscopy analysis.
Treatment
At the present time, the treatment is led to ameliorate
the course of the disease and to prevent or treat
pulmonary and cardiac impairment. Antisense oligo-
nucleotide has been shown to have a good response in
Fig. 8 Severe myotonic dystrophy. Patient born with
polyhydramnios with congenital talipes equino-varus responsive
to Mestinol
Fig. 9 A girl, 2 years old, affected by nemalinic myopathy
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the mouse model for myotonic dystrophy, and it is in
course of trial in humans [48]
There is no pharmacological treatment for the CMDs.
However, physiotherapic treatment is advisable to prevent
joints deformity, muscles retractions, and scoliosis. Sup-
portive treatment with non invasive respiratory support in
case of respiratory distress, correction of gastro-esophageal
reflux, support in cardiac failure, treatment of respiratory
infections, and nutritional treatment with new modality
must be constantly carried out. This treatment strategy has
allowed these patients to a wider and better survival.
Conclusions
CMDs are a group of disorders that involve more than
only muscles; other body structures including the brain,
eyes, and heart may be affected. Diagnosis is not easy,
and the time when a muscular biopsy should be per-
formed is not easy to be established. However, muscular
biopsy becomes worthy to indicate the correct molecu-
lar/genetic analysis. The course of any of these forms is
usually severe. Nutritional and respiratory support have
prolonged the life of these children, but early fatal
outcome is typical. Performing clinical and molecular
diagnosis is extremely important for genetic counseling,
prognosis, and anticipatory treatment and also for pro-
spective treatment.
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